Literature DB >> 19530242

Cyr61 downmodulation potentiates the anticancer effects of zoledronic acid in androgen-independent prostate cancer cells.

Monica Marra1, Daniele Santini, Giuseppina Meo, Bruno Vincenzi, Silvia Zappavigna, Alfonso Baldi, Maciej Rosolowski, Giuseppe Tonini, Markus Loeffler, Ruth Lupu, Santolo Rosario Addeo, Alberto Abbruzzese, Alfredo Budillon, Michele Caraglia.   

Abstract

We have analyzed the gene modulation induced by zoledronic acid (ZOL) in androgen-resistant prostate cancer PC3 cells with cDNA microarray platform to identify new molecular targets of ZOL in prostate cancer. The gene coding for cysteine-rich, angiogenic inducer, 61 (CYR61) resulted highly downregulated with a fold change of 5.58. Therefore, we have studied the effects of ZOL on CYR61 protein product, and we have found that CYR61 protein expression was decreased significantly after exposure to ZOL. The effect of ZOL on CYR61 expression was dose and time dependent was due to a reduced transcriptional activity of CYR61 promoter. Moreover, the effects induced by ZOL were paralleled by decreased activation of Ras-Raf-1- and Akt-dependent pathways that was dependent from isoprenylation inhibition, since it was antagonized by the addition of geranylgeraniol. Finally, we have investigated the role of CYR61 in the regulation of growth inhibition and invasion/motility of PC3 cells using a shRNA for CYR61 to downregulate the expression of CYR61 protein. The enhanced inhibition of proliferation and motility/invasion induced by ZOL by S-phase accumulation. In the same experimental conditions, CYR61 protein downregulation potentiated the inactivation of the Ras-dependent proliferation pathway and cell cycle inhibitors p21 and p27 expression. (c) 2009 UICC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19530242     DOI: 10.1002/ijc.24648

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  14 in total

Review 1.  Direct antitumour activity of zoledronic acid: preclinical and clinical data.

Authors:  Joaquim Bosch-Barrera; Sofía D Merajver; Javier A Menéndez; Catherine Van Poznak
Journal:  Clin Transl Oncol       Date:  2011-03       Impact factor: 3.405

2.  CCN1, a candidate target for zoledronic acid treatment in breast cancer.

Authors:  Ingrid Espinoza; Hong Liu; Robert Busby; Ruth Lupu
Journal:  Mol Cancer Ther       Date:  2011-03-10       Impact factor: 6.261

3.  Hepatocyte growth factor induces breast cancer cell invasion via the PI3K/Akt and p38 MAPK signaling pathways to up-regulate the expression of COX2.

Authors:  Wenbin Kuang; Qiuchan Deng; Chuntao Deng; Wensheng Li; Shaowei Shu; Meirong Zhou
Journal:  Am J Transl Res       Date:  2017-08-15       Impact factor: 4.060

4.  Analysis of molecular mechanisms and anti-tumoural effects of zoledronic acid in breast cancer cells.

Authors:  Lavinia Insalaco; Francesca Di Gaudio; Marianna Terrasi; Valeria Amodeo; Stefano Caruso; Lidia Rita Corsini; Daniele Fanale; Naomi Margarese; Daniele Santini; Viviana Bazan; Antonio Russo
Journal:  J Cell Mol Med       Date:  2012-09       Impact factor: 5.310

5.  Acquired resistance to zoledronic acid and the parallel acquisition of an aggressive phenotype are mediated by p38-MAP kinase activation in prostate cancer cells.

Authors:  M R Milone; B Pucci; F Bruzzese; C Carbone; G Piro; S Costantini; F Capone; A Leone; E Di Gennaro; M Caraglia; A Budillon
Journal:  Cell Death Dis       Date:  2013-05-23       Impact factor: 8.469

6.  Inhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acid.

Authors:  Toni Ibrahim; Laura Mercatali; Emanuele Sacanna; Anna Tesei; Silvia Carloni; Paola Ulivi; Chiara Liverani; Francesco Fabbri; Michele Zanoni; Wainer Zoli; Dino Amadori
Journal:  Cancer Cell Int       Date:  2012-11-22       Impact factor: 5.722

7.  Bisphosphonates and cancer: what opportunities from nanotechnology?

Authors:  Giuseppe De Rosa; Gabriella Misso; Giuseppina Salzano; Michele Caraglia
Journal:  J Drug Deliv       Date:  2013-03-04

8.  The Regulation of Matrix Metalloproteinase Expression and the Role of Discoidin Domain Receptor 1/2 Signalling in Zoledronate-treated PC3 Cells.

Authors:  Buket Reel; Ceren Gonen Korkmaz; Mehmet Zuhuri Arun; Gokce Yildirim; Deniz Ogut; Aysegul Kaymak; Serap Cilaker Micili; Bekir Ugur Ergur
Journal:  J Cancer       Date:  2015-08-28       Impact factor: 4.207

9.  The kinetochore protein Cenp-F is a potential novel target for zoledronic acid in breast cancer cells.

Authors:  Hannah K Brown; Penelope D Ottewell; Robert E Coleman; Ingunn Holen
Journal:  J Cell Mol Med       Date:  2011-03       Impact factor: 5.310

10.  Urotensin II receptor determines prognosis of bladder cancer regulating cell motility/invasion.

Authors:  Renato Franco; Silvia Zappavigna; Vincenzo Gigantino; Amalia Luce; Monica Cantile; Margherita Cerrone; Gaetano Facchini; Sisto Perdonà; Sandro Pignata; Giuseppe Di Lorenzo; Sergio Chieffi; Giovanni Vitale; Marco De Sio; Alessandro Sgambato; Gerardo Botti; Ali Munaim Yousif; Ettore Novellino; Paolo Grieco; Michele Caraglia
Journal:  J Exp Clin Cancer Res       Date:  2014-06-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.